

Washington University School of Medicine

Digital Commons@Becker

---

Open Access Publications

---

2018

## Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies

Celeste M. Karch

*Washington University School of Medicine in St. Louis*

Natalie Wen

*Washington University School of Medicine in St. Louis*

et al.

Follow this and additional works at: [https://digitalcommons.wustl.edu/open\\_access\\_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Please let us know how this document benefits you.

---

### Recommended Citation


Karch, Celeste M.; Wen, Natalie; and et al., "Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies." *PLoS Medicine*. 15, 1. e1002487. (2018).  
[https://digitalcommons.wustl.edu/open\\_access\\_pubs/6813](https://digitalcommons.wustl.edu/open_access_pubs/6813)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [vanam@wustl.edu](mailto:vanam@wustl.edu).

RESEARCH ARTICLE

# Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies

Iris Broce<sup>1\*</sup>, Celeste M. Karch<sup>2</sup>, Natalie Wen<sup>2</sup>, Chun C. Fan<sup>3</sup>, Yunpeng Wang<sup>4,5</sup>, Chin Hong Tan<sup>1</sup>, Naomi Kouri<sup>6</sup>, Owen A. Ross<sup>6</sup>, Günter U. Höglinger<sup>7,8,9</sup>, Ulrich Müller<sup>10</sup>, John Hardy<sup>11</sup>, International FTD-Genomics Consortium<sup>†</sup>, Parastoo Momeni<sup>12</sup>, Christopher P. Hess<sup>1</sup>, William P. Dillon<sup>1</sup>, Zachary A. Miller<sup>13</sup>, Luke W. Bonham<sup>13</sup>, Gil D. Rabinovici<sup>13</sup>, Howard J. Rosen<sup>13</sup>, Gerard D. Schellenberg<sup>14</sup>, Andre Franke<sup>15</sup>, Tom H. Karlsen<sup>16,17,18</sup>, Jan H. Veldink<sup>19</sup>, Raffaele Ferrari<sup>11</sup>, Jennifer S. Yokoyama<sup>13</sup>, Bruce L. Miller<sup>13</sup>, Ole A. Andreassen<sup>4,5</sup>, Anders M. Dale<sup>3,20,21</sup>, Rahul S. Desikan<sup>1,13\*</sup>, Leo P. Sugrue<sup>1\*</sup>



## OPEN ACCESS

**Citation:** Broce I, Karch CM, Wen N, Fan CC, Wang Y, Hong Tan C, et al. (2018) Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. *PLoS Med* 15(1): e1002487. <https://doi.org/10.1371/journal.pmed.1002487>

**Academic Editor:** Carol Brayne, University of Cambridge, UNITED KINGDOM

**Received:** July 3, 2017

**Accepted:** December 5, 2017

**Published:** January 9, 2018

**Copyright:** © 2018 Broce et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The data generated by the International FTD-Genomics Consortium (IFGC) are available upon request to protect patient information and can be accessed at—<https://ifgcsite.wordpress.com/data-access/>. The data contained within the National Institute on Aging Genetics of Alzheimer's Disease Data Storage (NIAGADS)—<https://www.niagads.org/datasets/ng00045>, UK Brain Expression Consortium (Braineac)—<http://braineac.org>, Project MinE data browser—<http://databrowser.projectmine.com>, and Gene Expression Omnibus (GEO) database—

**1** Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, United States of America, **2** Department of Psychiatry, Washington University, St. Louis, Missouri, United States of America, **3** Department of Cognitive Sciences, University of California, San Diego, La Jolla, California, United States of America, **4** Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway, **5** Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway, **6** Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America, **7** Department of Neurology, Technical University of Munich, Munich, Germany, **8** German Center for Neurodegenerative Diseases (DZNE), Munich, Germany, **9** Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, **10** Institut für Humangenetik, Justus-Liebig-Universität, Giessen, Germany, **11** Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom, **12** Laboratory of Neurogenetics, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America, **13** Department of Neurology, University of California, San Francisco, San Francisco, California, United States of America, **14** Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **15** Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany, **16** Norwegian PSC Research Center, Research Institute of Internal Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway, **17** Division of Gastroenterology, Institute of Medicine, University of Bergen, Bergen, Norway, **18** K.G. Jebsen Inflammation Research Centre, Research Institute of Internal Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway, **19** Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands, **20** Department of Radiology, University of California, San Diego, La Jolla, California, United States of America, **21** Department of Neurosciences, University of California, San Diego, La Jolla, California, United States of America

<sup>†</sup> Membership of the International FTD-Genomics Consortium is provided in [S1 Acknowledgments](#).

\* [iris.broce@ucsf.edu](mailto:iris.broce@ucsf.edu) (IB); [rahul.desikan@ucsf.edu](mailto:rahul.desikan@ucsf.edu) (RSD); [leo.sugrue@ucsf.edu](mailto:leo.sugrue@ucsf.edu) (LPS)

## Abstract

### Background

Converging evidence suggests that immune-mediated dysfunction plays an important role in the pathogenesis of frontotemporal dementia (FTD). Although genetic studies have shown that immune-associated loci are associated with increased FTD risk, a systematic investigation of genetic overlap between immune-mediated diseases and the spectrum of FTD-related disorders has not been performed.

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13162> are publicly available.

**Funding:** Primary support for data analyses was provided by National Institutes of Health grants AG046374 (CK), U24DA041123 (AD, LS, RD), National Alzheimer's Coordinating Center (NACC) Junior Investigator (JI) Award (RD), RSNA Resident/Fellow Grant (RD), Foundation of ASNR Alzheimer's Imaging Grant (RD), Alzheimer's Society Grant 284 (RF), ARRS/ASNR Scholar Award (LS), and the Tau Consortium (JY, GDR). Additional support was provided by the Larry L. Hillblom Foundation 2016-A-005-SUP (JY), AFTD Susan Marcus Memorial Fund Clinical Research Grant (JY), NIA K01 AG049152 (JY), P01-AG-017586 (GDS), and the Bluefield Project to Cure FTD (JY). GH was funded by the Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2 & Munich Cluster for Systems Neurology SyNergy), the German Federal Ministry of Education and Research (BMBF, 01KU1403A EpiPD, 01EK1605A HitTau), the Bavarian Ministry for Education, Culture, Science and Art (Grant 8810001412 ForIPS), the NOMIS foundation (FTLD project). The PSP-GWAS was funded by a grant from the CurePSP Foundation, the Peebler PSP Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** I have read the journal's policy and the authors of this manuscript have the following competing interests: OAA reports patent pending for statistical genetics tool. OAA also received speakers's honorarium from Lundbeck. JHV's institute received consultancy fees from Vertex Pharmaceuticals. JH reports consulting for Cytos Genetics. AMD reports that he is a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. AMD is a member of the Scientific Advisory Board of Human Longevity, Inc., and receives funding through research grants with General Electric Healthcare (the terms of these arrangements have been reviewed by and approved by the University of California, San Diego in accordance with its conflict of interest policies). AMD has a pending patent entitled "SYSTEMS AND METHODS FOR IDENTIFYING POLYMORPHISMS" through UC San Diego. GDR declared to receive research support from Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare and Piramal. GDR also served on Scientific Advisory Boards for: Merck, Genentech, Roche. BM is a member of the Editorial Board of PLOS Medicine.

**Abbreviations:** ALS, amyotrophic lateral sclerosis; CBD, corticobasal degeneration; CD, Crohn

## Methods and findings

Using large genome-wide association studies (GWASs) (total  $n = 192,886$  cases and controls) and recently developed tools to quantify genetic overlap/pleiotropy, we systematically identified single nucleotide polymorphisms (SNPs) *jointly* associated with FTD-related disorders—namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS)—and 1 or more immune-mediated diseases including Crohn disease, ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), and psoriasis. We found up to 270-fold genetic enrichment between FTD and RA, up to 160-fold genetic enrichment between FTD and UC, up to 180-fold genetic enrichment between FTD and T1D, and up to 175-fold genetic enrichment between FTD and CeD. In contrast, for CBD and PSP, only 1 of the 6 immune-mediated diseases produced genetic enrichment comparable to that seen for FTD, with up to 150-fold genetic enrichment between CBD and CeD and up to 180-fold enrichment between PSP and RA. Further, we found minimal enrichment between ALS and the immune-mediated diseases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold). For FTD, at a conjunction false discovery rate  $< 0.05$  and after excluding SNPs in linkage disequilibrium, we found that 8 of the 15 identified loci mapped to the *human leukocyte antigen (HLA)* region on Chromosome (Chr) 6. We also found novel candidate FTD susceptibility loci within *LRRK2* (*leucine rich repeat kinase 2*), *TBKB1* (*TBK1 binding protein 1*), and *PGBD5* (*piggyBac transposable element derived 5*). Functionally, we found that the expression of FTD-immune pleiotropic genes (particularly within the *HLA* region) is altered in post-mortem brain tissue from patients with FTD and is enriched in microglia/macrophages compared to other central nervous system cell types. The main study limitation is that the results represent only clinically diagnosed individuals. Also, given the complex interconnectedness of the *HLA* region, we were not able to define the specific gene or genes on Chr 6 responsible for our pleiotropic signal.

## Conclusions

We show immune-mediated genetic enrichment specifically in FTD, particularly within the *HLA* region. Our genetic results suggest that for a subset of patients, immune dysfunction may contribute to FTD risk. These findings have potential implications for clinical trials targeting immune dysfunction in patients with FTD.

## Author summary

### Why was this study done?

- Frontotemporal dementia (FTD) is the leading cause of dementia in individuals less than 65 years old.
- Currently, there is no approved treatment of FTD and no diagnostic tests for predicting disease onset or measuring progression.
- Increasing evidence suggests that inflammation and immune system dysfunction play an important role in the pathogenesis of FTD.

disease; CeD, celiac disease; Chr, Chromosome; *cis*-eQTL, *cis*-expression quantitative trait locus; CNS, central nervous system; FDR, false discovery rate; FTD, frontotemporal dementia; FTD-U, frontotemporal lobar degeneration with ubiquitinated inclusions; GWAS, genome-wide association study; IFGC, International FTD-Genomics Consortium; LD, linkage disequilibrium; NIAGADS, National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site; PSOR, psoriasis; PSP, progressive supranuclear palsy; RA, rheumatoid arthritis; SMR, summary-data-based Mendelian randomization; SNP, single nucleotide polymorphism; T1D, type 1 diabetes; UC, ulcerative colitis.

## What did the researchers do and find?

- We used summary data from genome-wide association studies to investigate genetic overlap, or “pleiotropy,” between FTD and a variety of immune-mediated diseases.
- Through this approach, we found extensive FTD-immune genetic overlap within the *HLA* region on Chromosome 6, an area rich in genes related to microglial function, as well as in 3 genes not previously identified as contributing to the pathophysiology of FTD.
- Pointing to the functional relevance of these genetic results, we found that these candidate FTD-immune genes are differentially expressed in postmortem brains from patients with FTD compared to controls, and in microglia/macrophages compared with other central nervous system cells.
- Using bioinformatics tools, we explored protein and genetic interactions among our candidate FTD-immune genes. These results suggest that rather than a few individual loci, large portions of the *HLA* region may be associated with increased FTD risk.

## What do these findings mean?

- Immune dysfunction may play a role in the pathophysiology of a subset of FTD cases.
- For a subset of patients in whom immune dysfunction in general—and microglial activation in particular—is central to disease pathophysiology, anti-inflammatory treatment is an important area for further investigation.

## Introduction

Frontotemporal dementia (FTD) is a fatal neurodegenerative disorder and the leading cause of dementia among individuals younger than 65 years of age [1]. Given rapid disease progression and the absence of disease-modifying therapies, there is an urgent need to better understand FTD pathobiology to accelerate development of novel preventive and therapeutic strategies.

Converging molecular, cellular, genetic, and clinical evidence suggests that neuroinflammation plays a role in FTD pathogenesis. Complement factors and activated microglia, key components of inflammation, have been established as histopathologic features in brains of patients [2] and in mouse models of FTD [3,4]. Genome-wide association studies (GWASs) have shown that single nucleotide polymorphisms (SNPs) within the immune-regulating *human leukocyte antigen* (*HLA*) region on Chromosome (Chr) 6 are associated with elevated FTD risk [5]. Importantly, there is increased prevalence of immune-mediated diseases among patients with FTD [6,7]. Together, these findings suggest that immune-related mechanisms may contribute to and potentially drive FTD pathology.

Recent work in human molecular genetics has emphasized “pleiotropy,” where variations in a single gene can affect multiple, seemingly unrelated phenotypes [8]. In the present study, we systematically evaluated genetic pleiotropy between FTD and immune-mediated diseases. Using large neurodegenerative GWASs and recently developed tools to estimate polygenic pleiotropy, we sought to identify SNPs *jointly* associated with FTD-related disorders [9,10]—namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and

amyotrophic lateral sclerosis (ALS)—and 1 or more immune-mediated diseases including Crohn disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), and psoriasis (PSOR).

## Methods

### Participant samples

We conducted a meta-analysis of summary data obtained from published data. More specifically, we evaluated complete GWAS results in the form of summary statistics ( $p$ -values and odds ratios) for FTD, CBD, PSP, and ALS and 6 immune-mediated diseases, including CD [11], UC [12], RA [13], T1D [14], CeD [15], and PSOR [16] (see Table 1). We obtained FTD GWAS summary statistic data from phase I of the International FTD-Genomics Consortium (IFGC), which consisted of 2,154 clinical FTD cases and 4,308 controls with genotyped and imputed data at 6,026,384 SNPs (Table 1; for additional details, see [5]). The FTD dataset included multiple clinically diagnosed FTD subtypes: behavioral variant (bvFTD), semantic dementia (sdFTD), primary nonfluent progressive aphasia (pnfaFTD), and FTD overlapping with motor neuron disease (mndFTD). These FTD cases and controls were recruited from 44 international research groups and diagnosed according to the Neary criteria [17]. The institutional review boards of all participating institutions approved the procedures for all IFGC sub-studies. Written informed consent was obtained from all participants or surrogates. We obtained CBD GWAS summary statistic data from 152 CBD cases and 3,311 controls at 533,898 SNPs (Table 1; for additional details, see [18]). The CBD cases were collected from 8 institutions, and controls were recruited from the Children's Hospital of Philadelphia. CBD was neuropathologically diagnosed using the National Institutes of Health Office of Rare Diseases Research criteria [19]. The institutional review boards of all participating institutions approved the procedures for CBD GWAS data. Written informed consent was obtained from all participants or surrogates. We obtained PSP GWAS summary statistic data (stage 1) from the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIA-GADS, <https://www.niagads.org>) for 1,114 individuals with autopsy-confirmed PSP and 3,247 controls at 531,451 SNPs (Table 1; for additional details, see [20]). The institutional review boards of all participating institutions approved the procedures for all NIAGADS sub-studies. Written informed consent was obtained from all participants or surrogates. We obtained ALS GWAS summary statistic data from 12,577 ALS cases and 23,475 controls at 18,741,501 SNPs (Table 1; for additional details, see [21]). The ALS GWAS summary statistics and sequenced variants are publicly available through the Project MinE Data Browser (<http://databrowser.projectmine.com>). The institutional review boards of all participating institutions approved

**Table 1. Summary data from all genome-wide association studies used in the current study.**

Disorder/disease	Abbreviation	Total <i>N</i>	Number of SNPs	Reference
Frontotemporal dementia	FTD	6,462	6,026,384	[5]
Corticobasal degeneration	CBD	3,463	533,898	[18]
Progressive supranuclear palsy	PSP	4,361	531,451	[20]
Amyotrophic lateral sclerosis	ALS	36,052	18,741,501	[21]
Crohn disease	CD	51,109	942,858	[11]
Ulcerative colitis	UC	26,405	1,273,589	[12]
Rheumatoid arthritis	RA	25,708	2,554,714	[13]
Type 1 diabetes	T1D	16,559	841,622	[14]
Celiac disease	CeD	15,283	528,969	[15]
Psoriasis	PSOR	7,484	1,121,166	[16]

<https://doi.org/10.1371/journal.pmed.1002487.t001>

the procedures for all ALS GWAS sub-studies. Written informed consent was obtained from all participants or surrogates.

## Genetic enrichment statistical analyses

The pleiotropic enrichment strategies implemented here were derived from previously published stratified false discovery rate (FDR) methods [22,23]. For given phenotypes A and B, pleiotropic “enrichment” between phenotype A and phenotype B exists if the proportion of SNPs or genes associated with phenotype A increases as a function of increased association with phenotype B. To assess for enrichment, we constructed fold enrichment plots of nominal  $-\log_{10}(p)$ -values for all FTD-related-disorder SNPs and for subsets of SNPs determined by the significance of their association with the 6 immune-mediated diseases. In fold enrichment plots, the presence of enrichment is reflected as an upward deflection of the curve for phenotype A with increasing strength of association with phenotype B. To assess for polygenic effects below the standard GWAS significance threshold, we focused the fold enrichment plots on SNPs with nominal  $-\log_{10}(p) < 7.3$  (corresponding to  $p > 5 \times 10^{-8}$ ). The enrichment seen can be directly interpreted in terms of the true discovery rate ( $1 - \text{FDR}$ ).

To identify specific loci jointly involved with each of the 4 FTD-related disorders and the 6 immune-mediated diseases, we computed conjunction FDRs. The conjunction FDR is a test of association between 2 traits [22]. Briefly, the conjunction FDR, denoted by  $\text{FDR}_{\text{trait1} \& \text{trait2}}$ , is defined as the posterior probability that a SNP is null for either trait or for both simultaneously, given that the  $p$ -values for both traits are as small, or smaller, than the observed  $p$ -values. Unlike the conditional FDR, which ranks disease/primary-phenotype-associated SNPs based on genetic “relatedness” with secondary phenotypes [24], the conjunction FDR minimizes the possibility/likelihood of a single phenotype driving the common association signal. The conjunction FDR therefore tends to be more conservative and specifically pinpoints pleiotropic loci shared between the traits/diseases of interest. We used an overall FDR threshold of  $< 0.05$ , which means 5 expected false discoveries per 100 reported. To visualize the results of our conjunction FDR analysis, we constructed Manhattan plots to illustrate the genomic location of the pleiotropic loci. We ranked all SNPs based on the conjunction FDR and removed SNPs in linkage disequilibrium ( $r^2 > 0.2$ ) with any higher ranked SNP. Key aspects and detailed information on fold enrichment plots, Manhattan plots, and conjunction FDRs can be found in prior reports [22,23,25,26].

## Functional evaluation of shared risk loci

To assess whether SNPs that are shared between FTD and immune-mediated disease modify gene expression, we identified *cis*-expression quantitative trait loci (*cis*-eQTLs, defined as variants within 1 Mb of a gene’s transcription start site) associated with shared FTD–immune SNPs and measured their regional brain expression in a publicly available dataset of normal control brains (UK Brain Expression Consortium; <http://braineac.org/>) [27]. We also evaluated *cis*-eQTLs using a blood-based dataset [28]. We applied an analysis of covariance (ANCOVA) to test for associations between genotypes and gene expression. We tested SNPs using an additive model.

## Network-based functional association analyses

To evaluate potential protein and genetic interactions, co-expression, co-localization, and protein domain similarity for the functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes, we used GeneMANIA (<http://genemania.org>), an online web portal for bio-informatic assessment of gene networks [29]. In addition to visualizing the composite gene network, we also assessed the weights of individual components within the network [30].



## Gene expression alterations in FTD brains

To determine whether functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes are differentially expressed in the brains of FTD patients, we analyzed the gene expression of pleiotropic genes. Postmortem expression data from the brains of 17 patients with frontotemporal lobar degeneration with ubiquitinated inclusions (FTD-U) (with and without progranulin [*GRN*] mutations) and 11 controls were obtained from a publically available dataset (Gene Expression Omnibus [GEO] dataset GSE13162; for additional details, see [31]). These data consist of global gene expression profiles from all histopathologically available regions from human FTD-U and control brains (frontal cortex, hippocampus, and cerebellum) analyzed on the Affymetrix U133A microarray platform. Given the small sample size of each individual region, we combined all 3 regions to maximize statistical power. Details about this dataset and analysis—including the human brain samples used, RNA extraction and hybridization methods, microarray quality control, and microarray data analysis—are provided in the original report [31].

## Evaluation of cell classes within the brain


Using a publicly available RNA-sequencing transcriptome and splicing database [32], we ascertained whether the functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes were expressed by specific cell classes within the brain. The 8 cell types surveyed were neurons, fetal and mature astrocytes, oligodendrocyte precursor cells, newly formed oligodendrocytes, myelinating oligodendrocytes, microglia/macrophages (henceforth “microglia”), endothelial cells, and pericytes (for additional details, see [32]).

## Results

### Shared genetic risk between FTD and immune-mediated disease

Using progressively stringent *p*-value thresholds for FTD SNPs (i.e., increasing values of nominal  $-\log_{10}[p]$ ), we observed genetic enrichment for FTD as a function of several immune-mediated diseases (Fig 1). More specifically, we found strong (up to 270-fold) genetic enrichment between FTD and RA, and comparable enrichment between FTD and UC, T1D, and CeD, with weaker enrichment between FTD and PSOR and CD.

At a conjunction FDR < 0.05, we identified 21 SNPs that were associated with both FTD and immune-mediated diseases (Fig 2; Table 2). Five of these SNPs demonstrated the opposite direction of allelic effect between FTD and the immune-mediated diseases (Table 2): (1) rs9261536, nearest gene = *TRIM15*; (2) rs3094138, nearest gene = *TRIM26*; (3) rs9268877, nearest gene = *HLA-DRA*; (4) rs10484561, nearest gene = *HLA-DQB1*; and (5) rs2269423, nearest gene = *AGPAT1*. Of the remaining 16, 2 SNPs showed strong linkage disequilibrium (LD), suggesting that they reflected the same signal: rs204991 and rs204989 (nearest gene: *GPSM3*; pairwise  $D' = 1$ ,  $r^2 = 1$ ). After excluding SNPs that demonstrated the opposite direction of allelic effect and SNPs that were in LD, we found that 8 of the remaining 15 identified loci mapped to the *HLA* region, suggesting that *HLA* markers were critical in driving our results. To test this hypothesis, we repeated our enrichment analysis after removing all SNPs in LD with  $r^2 > 0.2$  within 1 Mb of *HLA* variants (based on 1000 Genomes Project LD structure). After removing *HLA* SNPs, we saw considerable attenuation of genetic enrichment in FTD as a function of immune-mediated disease (Fig 3), suggesting that the observed overlap between immune-related diseases and FTD was largely driven by the *HLA* region. Further, to determine causal associations for FTD and the 6 immune-mediated diseases, we applied the recently developed summary-data-based Mendelian randomization (SMR; <http://cnsgenomics.com/>



**Fig 1. Fold enrichment plots of enrichment versus nominal  $-\log_{10}(p)$ -values (corrected for inflation) in frontotemporal dementia (FTD) below the standard genome-wide association study threshold of  $p < 5 \times 10^{-8}$  as a function of significance of association with 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of  $-\log_{10}(p) > 0$ ,  $-\log_{10}(p) > 1$ , and  $-\log_{10}(p) > 2$  correspond to  $p < 1$ ,  $p < 0.1$ , and  $p < 0.01$ , respectively. The dark blue line indicates all SNPs.

<https://doi.org/10.1371/journal.pmed.1002487.g001>


[software/smr/](#)) method. This approach is described in detail within the original report [33]. As shown in [S1 Table](#), results from the SMR analysis have identified significant loci that are consistent with the main findings, which suggest that *HLA* markers on Chr 6 are critical in driving our pleiotropic results.

Outside the *HLA* region, we found 7 other FTD- and immune-associated SNPs ([Fig 2](#); [Table 2](#)), including 2 in strong LD that mapped to the H1 haplotype of *microtubule associated protein tau* (*MAPT*) (LD: rs199533 and rs17572851; nearest genes: *NSF* and *MAPT*, pairwise  $D' = 1$ ,  $r^2 = 0.94$ ). Beyond *MAPT*, we found 5 additional novel loci associated with increased FTD risk, namely, (1) rs2192493 (Chr 7, nearest gene = *TWISTNB*), (2) rs7778450 (Chr 7, nearest gene = *TNS3*), (3) rs10216900 (Chr 8, nearest gene = *CR590356*), (4) rs10784359 (Chr 12, nearest gene = *SLC2A13*), and (5) rs2134297 (Chr 18, nearest gene = *DCC*) (see [Table 2](#) for additional details).

## Modest genetic enrichment between immune-mediated disease and PSP, CBD, and ALS

To evaluate the specificity of the shared genetic overlap between FTD and immune-mediated disease, we also evaluated overlap between the 6 immune-mediated diseases and CBD, PSP, and ALS. For CBD and PSP, a few of the immune-mediated diseases produced genetic





**Fig 2. “Conjunction” Manhattan plot of conjunction  $-\log_{10}(\text{FDR})$  values for frontotemporal dementia (FTD) given 6 immune-mediated diseases.** The 6 immune-related diseases were Crohn disease (CD; FTD|CD, red), ulcerative colitis (UC, FTD|UC, orange), type 1 diabetes (T1D, FTD|T1D, teal), rheumatoid arthritis (RA, FTD|RA, green), celiac disease (CeD, FTD|CeD, magenta), and psoriasis (PSOR, FTD|PSOR, blue). SNPs with conjunction  $-\log_{10}(\text{FDR}) > 1.3$  (i.e.,  $\text{FDR} < 0.05$ ) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.

<https://doi.org/10.1371/journal.pmed.1002487.g002>

enrichment comparable to that seen for FTD (S1–S3 Figs; S2–S4 Tables). For example, we found 150-fold genetic enrichment between CBD and CeD and 180-fold enrichment between PSP and RA. In contrast, we found minimal enrichment between ALS and the immune-mediated diseases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold) and between ALS and CeD (up to 15-fold).

At a conjunction  $\text{FDR} < 0.05$ , we identified several SNPs associated with both immune-mediated disease and CBD, PSP, or ALS (S4–S6 Figs; S2–S4 Tables). Few of the SNPs shared between CBD, PSP, or ALS and immune-mediated disease mapped to the *HLA* region. Only 2 PSP–immune SNPs mapped to the region of *MLN* and *IRF4* on Chr 6, and no CBD–immune or ALS–immune SNPs mapped to the *HLA* region (S4–S6 Figs; S2–S4 Tables).

Beyond the *HLA* region, we found several overlapping loci between the immune-mediated diseases and CBD, PSP, and ALS (S4–S6 Figs; S2–S4 Tables). For PSP, these were (1) rs7642229 with CeD (Chr 3, nearest gene = *XCRI*,  $\text{FDR} = 1.74 \times 10^{-2}$ ); (2) rs11718668 with CeD (Chr 3, nearest gene = *TERC*,  $\text{FDR} = 3.00 \times 10^{-2}$ ); (3) rs12203592 with CeD (Chr 6, nearest gene = *IRF4*,  $\text{FDR} = 4.17 \times 10^{-2}$ ); (4) rs1122554 with RA (Chr 6, nearest gene = *MLN*,  $\text{FDR} = 2.09 \times 10^{-2}$ ); and (5) rs3748256 with RA (Chr 11, nearest gene = *FAM76B*,  $\text{FDR} = 2.09 \times 10^{-2}$ ). For ALS, these were (1) rs3828599 with CeD (Chr 5, nearest gene = *GPX3*,  $\text{FDR} = 2.27 \times 10^{-2}$ ) and (2) rs10488631 with RA (Chr 7, nearest gene = *TNPO3*,  $\text{FDR} = 3.42 \times 10^{-2}$ ).

**Table 2. Overlapping loci between FTD and immune-mediated disease at a conjunction FDR < 0.05.**

SNP	Chr	Nearest gene	Reference immune disease	Reference immune disease <i>p</i> -value	Minimum conjunction FDR	FTD <i>p</i> -value	Direction of allelic effect
rs2269423	6	<i>AGPAT1</i>	CeD	$4.63 \times 10^{-2}$	$4.63 \times 10^{-2}$	$6.28 \times 10^{-1}$	+/-
rs3117097	6	<i>BTNL2</i>	RA	$8.21 \times 10^{-5}$	$8.21 \times 10^{-5}$	$7.19 \times 10^{-3}$	+/+
rs204989	6	<i>GPSM3</i>	UC	$2.90 \times 10^{-2}$	$9.02 \times 10^{-3}$	$2.58 \times 10^{-1}$	+/+
rs204991	6	<i>GPSM3</i>	T1D	$1.00 \times 10^{-2}$	$9.02 \times 10^{-3}$	$2.58 \times 10^{-1}$	+/+
rs17427887	6	<i>HLA-DQA2</i>	RA	$3.70 \times 10^{-2}$	$3.70 \times 10^{-2}$	$6.02 \times 10^{-1}$	-/-
rs10484561	6	<i>HLA-DQB1</i>	T1D	$1.86 \times 10^{-2}$	$1.71 \times 10^{-2}$	$4.17 \times 10^{-1}$	-/+
rs3135353	6	<i>HLA-DRA</i>	CD	$2.29 \times 10^{-2}$	$3.58 \times 10^{-3}$	$1.35 \times 10^{-1}$	+/+
rs9268852	6	<i>HLA-DRA</i>	UC	$1.25 \times 10^{-7}$	$1.25 \times 10^{-7}$	$1.03 \times 10^{-4}$	+/+
rs3129890	6	<i>HLA-DRA</i>	T1D	$5.54 \times 10^{-5}$	$5.54 \times 10^{-5}$	$7.19 \times 10^{-3}$	+/+
rs6457590	6	<i>HLA-DRA</i>	RA	$1.52 \times 10^{-2}$	$1.52 \times 10^{-2}$	$3.80 \times 10^{-1}$	+/+
rs9268877	6	<i>HLA-DRA</i>	RA	$3.64 \times 10^{-7}$	$1.25 \times 10^{-7}$	$1.03 \times 10^{-4}$	+/-
rs875142	6	<i>PAQR8</i>	CD	$4.62 \times 10^{-2}$	$4.62 \times 10^{-2}$	$5.51 \times 10^{-1}$	-/-
rs9261536	6	<i>TRIM15</i>	T1D	$4.31 \times 10^{-2}$	$4.31 \times 10^{-2}$	$6.98 \times 10^{-1}$	-/+
rs3094138	6	<i>TRIM26</i>	T1D	$4.63 \times 10^{-2}$	$2.87 \times 10^{-2}$	$6.28 \times 10^{-1}$	-/+
rs7778450	7	<i>TNS3</i>	CeD	$4.26 \times 10^{-2}$	$4.26 \times 10^{-2}$	$6.17 \times 10^{-1}$	-/-
rs2192493	7	<i>TWISTNB</i>	T1D	$4.17 \times 10^{-2}$	$4.17 \times 10^{-2}$	$6.09 \times 10^{-1}$	+/+
rs10216900	8	<i>CR590356</i>	T1D	$3.09 \times 10^{-2}$	$3.09 \times 10^{-2}$	$6.40 \times 10^{-1}$	+/+
rs10784359	12	<i>SLC2A13</i>	RA	$3.33 \times 10^{-2}$	$3.33 \times 10^{-2}$	$5.90 \times 10^{-1}$	+/+
rs17572851	17	<i>MAPT</i>	T1D	$2.47 \times 10^{-2}$	$2.47 \times 10^{-2}$	$5.90 \times 10^{-1}$	+/+
rs199533	17	<i>NSF</i>	CD	$3.90 \times 10^{-2}$	$1.95 \times 10^{-2}$	$4.56 \times 10^{-1}$	+/+
rs2134297	18	<i>DCC</i>	CeD	$3.11 \times 10^{-2}$	$3.11 \times 10^{-2}$	$5.73 \times 10^{-1}$	+/+

CD, Crohn disease; CeD, celiac disease; Chr, Chromosome; FDR, false discovery rate; FTD, frontotemporal dementia; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism; T1D, type 1 diabetes; UC, ulcerative colitis; -, negative effect estimate; +, positive effect estimate.


<https://doi.org/10.1371/journal.pmed.1002487.t002>

## cis-eQTL expression

To investigate whether shared FTD-immune SNPs modify gene expression, we evaluated *cis*-eQTLs in both brain and blood tissue types. At a previously established conservative Bonferroni-corrected *p*-value <  $3.9 \times 10^{-5}$  [34], we found significant *cis*-associations between shared SNPs and genes in the *HLA* region on Chr 6 in peripheral blood mononuclear cells, lymphoblasts, and the human brain (see S5 Table for gene expression associated with each SNP). We also found that rs199533 and rs17572851 on Chr 17 were significantly associated with *MAPT* ( $p = 2 \times 10^{-12}$ ) expression in the brain. Beyond the *HLA* and *MAPT* regions, notable *cis*-eQTLs included rs10784359 and *LRRK2* ( $p = 1.40 \times 10^{-7}$ ) and rs2192493 and *TBKBPI* ( $p = 1.29 \times 10^{-6}$ ) (see S5 Table).

## Protein-protein and co-expression networks

We found physical interaction and gene co-expression networks for the FTD-immune pleiotropic genes with significant *cis*-eQTLs (at a Bonferroni-corrected *p*-value <  $3.9 \times 10^{-5}$ ). We found robust co-expression between various *HLA* classes, further suggesting that large portions of the *HLA* region, rather than a few individual loci, may be involved with FTD (Fig 4; S6 Table). Interestingly, we found that several non-*HLA* functionally expressed FTD-immune genes, namely, *LRRK2*, *PGBD5*, and *TBKBPI*, showed co-expression with *HLA*-associated genes (Fig 4).



**Fig 3. Fold enrichment plots of enrichment (after removing all regions in linkage disequilibrium with *HLA* on Chromosome 6) versus nominal  $-\log_{10}(p)$ -values (corrected for inflation) in frontotemporal dementia (FTD) below the standard genome-wide association study threshold of  $p < 5 \times 10^{-8}$  as a function of significance of association with 6 immune-mediated diseases.** The 6 immune-mediated diseases were Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of  $-\log_{10}(p) > 0$ ,  $-\log_{10}(p) > 1$ , and  $-\log_{10}(p) > 2$  correspond to  $p < 1$ ,  $p < 0.1$ , and  $p < 0.01$ , respectively. The dark blue line indicates all SNPs.


<https://doi.org/10.1371/journal.pmed.1002487.g003>

## Genetic expression in FTD brains compared to controls

To investigate whether the FTD-immune pleiotropic genes with significant *cis*-eQTLs are differentially expressed in FTD brains, we compared gene expression in FTD-U brains to that in brains from neurologically healthy controls. We found significantly different levels of *HLA* gene expression in FTD-U brains compared to control brains (Table 3). This was true of FTD-U brains regardless of progranulin gene (*GRN*) mutation status. In spite of the fact that the FTD GWAS used to identify these genes was based on patients with sporadic FTD (without *GRN* mutations), *GRN* mutation carriers showed the greatest differences in *HLA* gene expression (Fig 5; Table 3). These findings are compatible with prior work showing microglial-mediated immune dysfunction in *GRN* mutation carriers [3].

## Microglial enrichment

For the FTD-immune pleiotropic genes with significant *cis*-eQTLs, across different central nervous system (CNS) cell types, we found significantly greater expression within microglia compared to neurons or fetal astrocytes (Fig 6A; Table 4). Interestingly, *HLA* genes showed the greatest degree of differential expression. Four of the FTD-immune *HLA*-associated genes, namely *HLA-DRA*, *AOAH*, *HLA-A*, and *HLA-C*, showed highest expression in microglia (ranging from 10 to 60 fragments per kilobase of transcript per million; see Fig 6B). In



### Networks

- Co-expression (90.93%)
- Shared protein domains (4.79%)
- Physical Interactions (2.03%)
- Predicted (1.82%)
- Co-localization (0.44%)

**Fig 4. Network interaction graph predominantly illustrating co-expression and shared protein domains for functionally expressed pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases.**

<https://doi.org/10.1371/journal.pmed.1002487.g004>

addition, *MAPT* was predominantly expressed in neurons, *LRRK2* in microglia, *PGBD5* in neurons, and *TBKBP1* in fetal astrocytes (Figs 6B and S7–S9).

## Discussion

We systematically assessed genetic overlap between 4 FTD-related disorders and several immune-mediated diseases. We found extensive genetic overlap between FTD and immune-mediated disease particularly within the *HLA* region on Chr 6, a region rich in genes associated with microglial function. This genetic enrichment was specific to FTD and did not extend

**Table 3. Genes associated with frontotemporal dementia (FTD) and immune-mediated disease differentially altered in patients with frontotemporal lobar degeneration with ubiquitinated inclusions (FTD-U) versus controls.**

Gene	Control versus FTD-U <i>p</i> -value	Control versus <i>GRN</i> + <i>p</i> -value
<i>AOAH</i>	0.631	<b>0.013</b>
<i>HLA-A</i>	0.622	<b>0.004</b>
<i>HLA-C</i>	0.372	<b>0.002</b>
<i>HLA-F</i>	0.592	<b>0.001</b>
<i>HLA-DRA (LOC101060835)</i>	<b>0.017</b>	<b>0.008</b>
<i>HLA-DRQ (HLA-DQB1)</i>	<b>0.009</b>	<b>0.001</b>
<i>MAPT</i>	0.376	0.090
<i>TBKBPI</i>	<b>0.005</b>	0.108
<i>PGBD5</i>	0.528	<b>0.016</b>
<i>LRRK2</i>	N/A	N/A

*p*-Values  $\leq 0.05$  are in bold.

N/A, not available.


<https://doi.org/10.1371/journal.pmed.1002487.t003>

to CBD, PSP, or ALS. Further, we found that shared FTD-immune gene variants were differentially expressed in FTD patients compared with controls, and in microglia compared with other CNS cells. Beyond the *HLA* region, by leveraging statistical power from large immune-mediated GWASs, we detected novel candidate FTD associations requiring validation within *LRRK2*, *TBKBPI*, and *PGBD5*. Considered together, these findings suggest that various microglia and inflammation-associated genes, particularly within the *HLA* region, may play a critical and selective role in FTD pathogenesis.

By combining GWASs from multiple studies and applying a pleiotropic approach, we identified genetic variants jointly associated with FTD-related disorders and immune-mediated disease. We found that the strength of genetic overlap with immune-mediated disease varies markedly across FTD-related disorders, with the strongest pleiotropic effects associated with FTD, followed by CBD and PSP, and the weakest pleiotropic effects associated with ALS. We identified 8 FTD- and immune-associated loci that mapped to the *HLA* region, a concentration of loci that was not observed for the other disorders. Indeed, only 2 PSP-immune pleiotropic SNPs and no CBD-immune or ALS-immune pleiotropic SNPs mapped to the *HLA* region. Previous work has identified particular *HLA* genes associated with CBD, PSP, and ALS [35,36]. In contrast, our current findings implicate large portions of the *HLA* region in the pathogenesis of FTD. Together, these results suggest that each disorder across the larger FTD spectrum has a unique relationship with the *HLA* region.

Our results also indicate that functionally expressed FTD-immune shared genetic variants are differentially expressed in FTD brains compared to controls and in microglia compared to other CNS cell types (Fig 6). Microglia play a role in the pathophysiology of *GRN*+ FTD. Progranulin is expressed in microglia [37], and *GRN* haploinsufficiency is associated with abnormal microglial activation and neurodegeneration [3]. It is perhaps expected, therefore, that *GRN*+ brains show differential expression of FTD-immune genes, even though these genetic variants were derived from a GWAS of patients with sporadic FTD (who lack *GRN* or other established FTD mutations). More surprising is the presence of similar enrichment in *GRN* – brains, suggesting that dysfunction of microglial-centered immune networks may be a common feature of FTD pathogenesis.

By leveraging statistical power from the large immune-mediated GWASs, we identified novel candidate FTD associations requiring validation within *LRRK2*, *TBKBPI*, and *PGBD5*




**Fig 5. Pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases are elevated in brains of patients with FTD with *GRN* mutation.** Expression for the genes with the largest effect sizes are plotted: (A) *HLA-A*, (B) *HLA-C*, (C) *HLA-DRQ*, and (D) *HLA-DRA*. Expression values were obtained from GSE13162 for FTD-U brains with and without *GRN* mutations and neuropathology-free controls. Horizontal bar represents mean  $\pm$  SEM.

<https://doi.org/10.1371/journal.pmed.1002487.g005>

and confirmed previously shown FTD-associated signal within the *MAPT* region. *LRRK2* mutations are a cause of Parkinson disease [38] and CD [39]. We previously described a potential link between FTD and the *LRRK2* locus [40], and another study using a small sample showed that *LRRK2* mutations may increase FTD risk [41]. Together, these results suggest that the extended *LRRK2* locus might influence FTD despite common genetic variants within *LRRK2* not reaching genome-wide significance in a large FTD GWAS [5]. We suggest that increased expression of *LRRK2* in microglia results in proinflammatory responses, possibly by modulating TNF-alpha secretion [42]. *TBKBP1* also modulates TNF-alpha signaling by binding to *TBK1* (*TANK binding kinase 1*) [43]; rare pathogenic variants in *TBK1* cause FTD-ALS [44–46]. Importantly, elevated CSF levels of TNF-alpha are a core feature of FTD [6,47]. Building on these findings, in our bioinformatics “network”-based analysis, we found that both *LRRK2* and *TBKBP1* interact with genes within the *HLA* region (Fig 4). Further, physical interactions between *MAPT* and the *HLA* network are compatible with research suggesting that under different conditions reactive microglia can either drive or mitigate tau pathology [48,49]. *MAPT* mutations, which disrupt the normal binding of tau protein to tubulin, account for a large proportion of familial FTD cases [50]. Together, these findings suggest that *LRRK2*, *TBKBP1*, and *MAPT* may, at least in part, influence FTD pathogenesis via *HLA*-related mechanisms.





**Fig 6. Microglia enrichment in genes associated with frontotemporal dementia (FTD) and immune-mediated disease.** FTD-immune genes were analyzed to determine the cell type in which each gene was most highly expressed [32]. (A) Bar plots showing the relative number of genes most highly expressed in each cell type. No genes were most highly expressed in endothelial cells or oligodendrocytes. See Table 4 for individual gene names. (B) Individual bar plots showing cell-type-specific expression for genes with the largest effect size. Note that the horizontal scale is not the same in all the plots. FPKM, fragments per kilobase of transcript per million.

<https://doi.org/10.1371/journal.pmed.1002487.g006>

**Table 4. Enrichment of genes associated with frontotemporal dementia (FTD) and immune-mediated disease in microglia compared with other central nervous system cells.**

Gene	Most enriched cell type
<i>AOAH</i>	Microglia/macrophage
<i>HLA-A</i>	Microglia/macrophage
<i>HLA-C</i>	Microglia/macrophage
<i>HLA-F</i>	Neurons
<i>HLA-DRA</i>	Microglia/macrophage
<i>HLA-DRQ</i>	Not found
<i>LRRC37A3</i>	Microglia/macrophage
<i>MAPT</i>	Neurons
<i>TRAM2</i>	Fetal astrocytes

No genes were most highly expressed in endothelial cells or oligodendrocytes.

<https://doi.org/10.1371/journal.pmed.1002487.t004>

This study has limitations. Particularly, in the original datasets that form the basis of our analysis, diagnosis of FTD was established clinically. Given the clinical overlap among neurodegenerative diseases, we cannot exclude the potential influence of clinical misdiagnosis. As such, our findings would benefit from confirmation in large pathologically confirmed cohorts. In addition, given the complex interconnectedness of the *HLA* region (see Fig 4), we also were not able to define the specific gene or genes on Chr 6 responsible for our pleiotropic signal. However, given the number of *HLA* loci associated with increased FTD risk, it may be the case that no single *HLA* variant will be clinically informative; rather, an *additive combination* of these microglia-associated genetic variants may better inform FTD risk. This possibility is supported by our observation that the expression levels of FTD-immune shared genetic variants differ *on average* between FTD brains and controls, but with considerable overlap between the two groups, again suggesting that no single variant is likely to be the determinant of FTD risk (Fig 5). Further, we acknowledge the lack of transcriptomic and epigenetic data that would help to identify possible causal associations and mechanisms driving our pleiotropic signal.

In conclusion, across a large cohort (total  $n = 192,886$  cases and controls), we used pleiotropy between FTD-related disorders and immune-mediated disease to identify several genes within the *HLA* region that are expressed within microglia and differentially expressed in the brains of patients with FTD. Building on prior work [6,7], our results support a disease model in which immune dysfunction is central to the pathophysiology of a subset of FTD cases. These findings have important implications for future work in FTD focused on monitoring microglial activation as a marker of disease progression and investigating anti-inflammatory treatments as modifiers of disease outcome.

## Supporting information

### S1 Acknowledgments.

(DOCX)

**S1 Fig. Fold enrichment plots of enrichment versus nominal  $-\log_{10}(p)$ -values (corrected for inflation) in corticobasal degeneration (CBD) below the standard genome-wide association study threshold of  $p < 5 \times 10^{-8}$  as a function of significance of association with 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of  $-\log_{10}(p) > 0$ ,  $-\log_{10}(p) > 1$ , and  $-\log_{10}(p) > 2$  correspond to  $p < 1$ ,  $p < 0.1$ , and  $p < 0.01$ , respectively. The dark blue line indicates all SNPs. (TIFF)

**S2 Fig. Fold enrichment plots of enrichment versus nominal  $-\log_{10}(p)$ -values (corrected for inflation) in progressive supranuclear palsy (PSP) below the standard genome-wide association study threshold of  $p < 5 \times 10^{-8}$  as a function of significance of association with 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of  $-\log_{10}(p) > 0$ ,  $-\log_{10}(p) > 1$ , and  $-\log_{10}(p) > 2$  correspond to  $p < 1$ ,  $p < 0.1$ , and  $p < 0.01$ , respectively. The dark blue line indicates all SNPs. (TIFF)

**S3 Fig. Fold enrichment plots of enrichment versus nominal  $-\log_{10}(p)$ -values (corrected for inflation) in amyotrophic lateral sclerosis (ALS) below the standard genome-wide association study threshold of  $p < 5 \times 10^{-8}$  as a function of significance of association with 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and

psoriasis (PSOR). The levels of  $-\log_{10}(p) > 0$ ,  $-\log_{10}(p) > 1$ , and  $-\log_{10}(p) > 2$  correspond to  $p < 1$ ,  $p < 0.1$ , and  $p < 0.01$ , respectively. The dark blue line indicates all SNPs.  
(TIFF)

**S4 Fig. “Conjunction” Manhattan plot of conjunction and conditional  $-\log_{10}(\text{FDR})$  values for corticobasal degeneration (CBD) given 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD; CBD|CD, red), ulcerative colitis (UC, CBD|UC, orange), type 1 diabetes (T1D, CBD|T1D, teal), rheumatoid arthritis (RA, CBD|RA, green), celiac disease (CeD, CBD|CeD, magenta), and psoriasis (PSOR, CBD|PSOR, blue). SNPs with conditional and conjunction  $-\log_{10}(\text{FDR}) > 1.3$  (i.e.,  $\text{FDR} < 0.05$ ) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.  
(TIFF)

**S5 Fig. “Conjunction” Manhattan plot of conjunction and conditional  $-\log_{10}(\text{FDR})$  values for progressive supranuclear palsy (PSP) given 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD; PSP|CD, red), ulcerative colitis (UC, PSP|UC, orange), type 1 diabetes (T1D, PSP|T1D, teal), rheumatoid arthritis (RA, PSP|RA, green), celiac disease (CeD, PSP|CeD, magenta), and psoriasis (PSOR, PSP|PSOR, blue). SNPs with conditional and conjunction  $-\log_{10}(\text{FDR}) > 1.3$  (i.e.,  $\text{FDR} < 0.05$ ) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.  
(TIFF)

**S6 Fig. “Conjunction” Manhattan plot of conjunction and conditional  $-\log_{10}(\text{FDR})$  values for amyotrophic lateral sclerosis (ALS) given 6 immune-mediated diseases.** The 6 immune-mediated diseases are Crohn disease (CD; ALS|CD, red), ulcerative colitis (UC, ALS|UC, orange), type 1 diabetes (T1D, ALS|T1D, teal), rheumatoid arthritis (RA, ALS|RA, green), celiac disease (CeD, ALS|CeD, magenta), and psoriasis (PSOR, ALS|PSOR, blue). SNPs with conditional and conjunction  $-\log_{10}(\text{FDR}) > 1.3$  (i.e.,  $\text{FDR} < 0.05$ ) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.  
(TIFF)

**S7 Fig. Individual bar plots showing cell-type-specific expression for *LRK2*.**  
(TIFF)

**S8 Fig. Individual bar plots showing cell-type-specific expression for *PGBD5*.**  
(TIFF)

**S9 Fig. Individual bar plots showing cell-type-specific expression for *TBKBPI*.**  
(TIFF)

**S1 Table. Summary-data-based Mendelian randomization results.**  
(DOCX)

**S2 Table. Overlapping loci between CBD and immune-mediated diseases at a conjunction  $\text{FDR} < 0.05$ .**  
(DOCX)

**S3 Table. Overlapping loci between PSP and immune-mediated diseases at a conjunction  $\text{FDR} < 0.05$ .**  
(DOCX)

**S4 Table. Overlapping loci between ALS and immune-mediated diseases at a conjunction FDR < 0.05.**

(DOCX)

**S5 Table. *cis*-eQTLs between FTD and immune-mediated disease shared risk SNPs and associated genes across a variety of tissues.**

(DOCX)

**S6 Table. Physical interaction and gene co-expression networks for the pleiotropic genes with significant *cis*-eQTLs.**

(DOCX)

## Acknowledgments

The authors thank the IFGC for providing phase I summary statistics data for these analyses. Further acknowledgments for the IFGC are provided in [S1 Acknowledgments](#).

## Author Contributions

**Conceptualization:** Iris Broce, Celeste M. Karch, Christopher P. Hess, Zachary A. Miller, Howard J. Rosen, Gerard D. Schellenberg, Jan H. Veldink, Raffaele Ferrari, Jennifer S. Yokoyama, Bruce L. Miller, Ole A. Andreassen, Anders M. Dale, Rahul S. Desikan, Leo P. Sugrue.

**Data curation:** Parastoo Momeni, William P. Dillon, Gil D. Rabinovici, Gerard D. Schellenberg, Andre Franke, Tom H. Karlsen, Raffaele Ferrari, Rahul S. Desikan.

**Formal analysis:** Iris Broce, Celeste M. Karch, Natalie Wen, Chun C. Fan, Chin Hong Tan, Luke W. Bonham, Jennifer S. Yokoyama, Ole A. Andreassen, Anders M. Dale, Rahul S. Desikan.

**Funding acquisition:** Rahul S. Desikan.

**Investigation:** Rahul S. Desikan, Leo P. Sugrue.

**Methodology:** Celeste M. Karch, Natalie Wen, Chun C. Fan, Yunpeng Wang, Naomi Kouri, Owen A. Ross, Günter U. Höglinger, Ulrich Muller, John Hardy, Jan H. Veldink, Raffaele Ferrari, Ole A. Andreassen, Anders M. Dale, Rahul S. Desikan, Leo P. Sugrue.

**Project administration:** Parastoo Momeni, Rahul S. Desikan, Leo P. Sugrue.

**Resources:** Parastoo Momeni, Rahul S. Desikan, Leo P. Sugrue.

**Software:** Rahul S. Desikan.

**Supervision:** Bruce L. Miller, Rahul S. Desikan, Leo P. Sugrue.

**Validation:** Rahul S. Desikan, Leo P. Sugrue.

**Visualization:** Rahul S. Desikan, Leo P. Sugrue.

**Writing – original draft:** Iris Broce, Natalie Wen, Chun C. Fan, Yunpeng Wang, Owen A. Ross, John Hardy, Parastoo Momeni, Christopher P. Hess, Gil D. Rabinovici, Howard J. Rosen, Andre Franke, Tom H. Karlsen, Jennifer S. Yokoyama, Bruce L. Miller, Rahul S. Desikan, Leo P. Sugrue.

**Writing – review & editing:** Iris Broce, Celeste M. Karch, Chun C. Fan, Chin Hong Tan, Naomi Kouri, Owen A. Ross, Günter U. Höglinger, Ulrich Muller, John Hardy, Christopher P. Hess, William P. Dillon, Zachary A. Miller, Luke W. Bonham, Gil D. Rabinovici,

Howard J. Rosen, Gerard D. Schellenberg, Andre Franke, Jan H. Veldink, Raffaele Ferrari, Jennifer S. Yokoyama, Bruce L. Miller, Ole A. Andreassen, Anders M. Dale, Rahul S. Desikan, Leo P. Sugrue.

## References

1. Vieira RT, Caixeta L, Machado S, Silva AC, Nardi AE, Arias-Carrión O, et al. Epidemiology of early-onset dementia: a review of the literature. *Clin Pract Epidemiol Ment Health*. 2013; 9(1):88–95.
2. Arnold SE, Han L-Y, Clark CM, Grossman M, Trojanowski JQ. Quantitative neurohistological features of frontotemporal degeneration. *Neurobiol Aging*. 2000; 21(6):913–9. PMID: [11124442](#)
3. Lui H, Zhang J, Makinson S, Cahill M, Kelley K, Huang H, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. *Cell*. 2016; 165(4):921–35. <https://doi.org/10.1016/j.cell.2016.04.001> PMID: [27114033](#)
4. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *J Exp Med*. 2010; 207(1):117–28. <https://doi.org/10.1084/jem.20091568> PMID: [20026663](#)
5. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al. Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurol*. 2014; 13(7):686–99. [https://doi.org/10.1016/S1474-4422\(14\)70065-1](https://doi.org/10.1016/S1474-4422(14)70065-1) PMID: [24943344](#)
6. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, et al. TDP-43 frontotemporal lobar degeneration and autoimmune disease. *J Neurol Neurosurg Psychiatry*. 2013; 84(9):956–62. <https://doi.org/10.1136/jnnp-2012-304644> PMID: [23543794](#)
7. Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, et al. Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts completing the picture. *Neurol Neuroimmunol Neuroinflamm*. 2016; 3(6):e301. <https://doi.org/10.1212/NXI.0000000000000301> PMID: [27844039](#)
8. Stearns FW. One hundred years of pleiotropy: a retrospective. *Genetics*. 2010; 186(3):767–73. <https://doi.org/10.1534/genetics.110.122549> PMID: [21062962](#)
9. Olney NT, Spina S, Miller BL. Frontotemporal dementia. *Neurol Clin*. 2017; 35(2):339–74. <https://doi.org/10.1016/j.ncl.2017.01.008> PMID: [28410663](#)
10. Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma. *Ann Neurol*. 2008; 64(1):4–14. <https://doi.org/10.1002/ana.21426> PMID: [18668533](#)
11. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet*. 2010; 42(12):1118–25. <https://doi.org/10.1038/ng.717> PMID: [21102463](#)
12. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet*. 2011; 43(3):246–52. <https://doi.org/10.1038/ng.764> PMID: [21297633](#)
13. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet*. 2010; 42(6):508–14. <https://doi.org/10.1038/ng.582> PMID: [20453842](#)
14. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat Genet*. 2009; 41(6):703–7. <https://doi.org/10.1038/ng.381> PMID: [19430480](#)
15. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. *Nat Genet*. 2010; 42(4):295–302. <https://doi.org/10.1038/ng.543> PMID: [20190752](#)
16. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. *Am J Hum Genet*. 2012; 90(4):636–47. <https://doi.org/10.1016/j.ajhg.2012.02.020> PMID: [22482804](#)
17. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black SA, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology*. 1998; 51(6):1546–54. PMID: [9855500](#)
18. Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. *Nat Commun*. 2015; 6:7247. <https://doi.org/10.1038/ncomms8247> PMID: [26077951](#)
19. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. *J Neuropathol Exp Neurol*. 2002; 61(11):935–46. PMID: [12430710](#)

20. Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang L-S, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet.* 2011; 43(7):699–705. <https://doi.org/10.1038/ng.859> PMID: 21685912
21. van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet.* 2016; 48(9):1043–8. <https://doi.org/10.1038/ng.3622> PMID: 27455348
22. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet.* 2013; 92(2):197–209. <https://doi.org/10.1016/j.ajhg.2013.01.001> PMID: 23375658
23. Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR, et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. *PLoS Genet.* 2013; 9(4):e1003455. <https://doi.org/10.1371/journal.pgen.1003455> PMID: 23637625
24. Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. *Mol Psychiatry.* 2015; 20(12):1588–95. <https://doi.org/10.1038/mp.2015.6> PMID: 25687773
25. Yokoyama JS, Wang Y, Schork AJ, Thompson WK, Karch CM, Cruchaga C, et al. Association between genetic traits for immune-mediated diseases and Alzheimer disease. *JAMA Neurol.* 2016; 73(6):691–7. <https://doi.org/10.1001/jamaneurol.2016.0150> PMID: 27088644
26. Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. *Acta Neuropathol.* 2017; 133(5):825–37. <https://doi.org/10.1007/s00401-017-1693-y> PMID: 28271184
27. Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R, et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat Neurosci.* 2014; 17(10):1418–28. <https://doi.org/10.1038/nn.3801> PMID: 25174004
28. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet.* 2013; 45(10):1238–43. <https://doi.org/10.1038/ng.2756> PMID: 24013639
29. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. The genemania prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res.* 2010; 38(Web Server issue):W214–20. <https://doi.org/10.1093/nar/gkq537> PMID: 20576703
30. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. *Genome Biol.* 2008; 9(Suppl 1):S4.
31. Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, et al. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. *Hum Mol Genet.* 2008; 17(10):1349–62. <https://doi.org/10.1093/hmg/ddn023> PMID: 18223198
32. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keefe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci.* 2014; 34(36):11929–47. <https://doi.org/10.1523/JNEUROSCI.1860-14.2014> PMID: 25186741
33. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet.* 2016; 48(5):481–7. <https://doi.org/10.1038/ng.3538> PMID: 27019110
34. Karch CM, Ezerskiy LA, Bertelsen S, Goate AM. Alzheimer's disease risk polymorphisms regulate gene expression in the ZCWPW1 and the CELF1 loci. *PLoS ONE.* 2016; 11(2):e0148717. <https://doi.org/10.1371/journal.pone.0148717> PMID: 26919393
35. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. *J Neuropathol Exp Neurol.* 2001; 60(6):647–57. PMID: 11398841
36. Dattola V, Famà F, Russo M, Calabrò RS, Logiudice AL, Grasso MG, et al. Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. *Neurol Sci.* 2017; 38(8):1501–3. <https://doi.org/10.1007/s10072-017-2939-0> PMID: 28421301
37. Toh H, Chitramuthu BP, Bennett HPJ, Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. *J Mol Neurosci.* 2011; 45(3):538. <https://doi.org/10.1007/s12031-011-9569-4> PMID: 21691802
38. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol.* 2008; 7(7):583–90. [https://doi.org/10.1016/S1474-4422\(08\)70117-0](https://doi.org/10.1016/S1474-4422(08)70117-0) PMID: 18539534



39. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet.* 2008; 40(8):955–62. <https://doi.org/10.1038/ng.175> PMID: 18587394
40. Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM, et al. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. *J Neurol Neurosurg Psychiatry.* 2017; 88(2):152–64. <https://doi.org/10.1136/jnnp-2016-314411> PMID: 27899424
41. Dächsel JC, Ross OA, Mata IF, Kachergus J, Toft M, Cannon A, et al. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. *Acta Neuropathol.* 2007; 113(5):601–6. <https://doi.org/10.1007/s00401-006-0178-1> PMID: 17151837
42. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, et al. LRRK2 inhibition attenuates microglial inflammatory responses. *J Neurosci.* 2012; 32(5):1602–11. <https://doi.org/10.1523/JNEUROSCI.5601-11.2012> PMID: 22302802
43. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, et al. A physical and functional map of the human tnfr-alpha/nf-kappa B signal transduction pathway. *Nat Cell Biol.* 2004; 6(2):97–105. <https://doi.org/10.1038/ncb1086> PMID: 14743216
44. Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. *Science.* 2015; 347(6229):1436–41. <https://doi.org/10.1126/science.aaa3650> PMID: 25700176
45. Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Müller K, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. *Nat Neurosci.* 2015; 18(5):631–6. <https://doi.org/10.1038/nn.4000> PMID: 25803835
46. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkerson R, et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. *Acta Neuropathol.* 2015; 130(1):77–92. <https://doi.org/10.1007/s00401-015-1436-x> PMID: 25943890
47. Sjögren M, Folkesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. *J Neurol Neurosurg Psychiatry.* 2004; 75(8):1107–11. <https://doi.org/10.1136/jnnp.2003.019422> PMID: 15258209
48. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain.* 2015; 138(6):1738–55.
49. Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct therapeutic mechanisms of tau antibodies. *J Biol Chem.* 2015; 290(35):21652–62. <https://doi.org/10.1074/jbc.M115.657924> PMID: 26126828
50. Rizzo P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. *Am J Hum Genet.* 1999; 64(2):414–21. <https://doi.org/10.1086/302256> PMID: 9973279